Opendata, web and dolomites


100% Bacteria free eggs for use in production of human and animal vaccines

Total Cost €


EC-Contrib. €






 OvaVAx project word cloud

Explore the words cloud of the OvaVAx project. It provides you a very rough idea of what is the project "OvaVAx" about.

moran    pandemic    ltd    ceo    1bn       manufacturing    seven    exceptionally    global    egg    chicken    agr       patent    vc    dr    annually    cagr    opportunity    specialises    industry    eliminate    demands    world    health    services    transgenics    expertise    biotechnology    vision    viral    innovative    globally    biopharma    size    manufacture    first    company    utilising    service    innovation    demand    led    caulfield    investors    ireland    catherine    superior    protected    immunisation    skills    2022    yields    eggs    specialist    manufacturers    89bn    lives    vaccines    commercially    avian    2021    usd    yield    coo    invested    protect    contamination    pull    serial    benefits    supplier    providers    contract    germ    91m    disruptive    populations    standards    worth    entrepreneurs    fertilised    considerable    market    12    good    leonard    group    vaccine    ovagen    gf    pharmaceutical    rapid    servicing    enterprise    ogl    pathogen    bacterial    industries    external    free    founders    48bn    spf    quality    whilst    team   

Project "OvaVAx" data sheet

The following table provides information about the project.


Organization address
postcode: F26PC79
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 3˙366˙875 €
 EC max contribution 2˙356˙812 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OVAGEN GROUP LIMITED IE (BALLINA) coordinator 2˙356˙812.00


 Project objective

Disruptive technology for improved quality and viral yield in egg-based vaccine production and other biotechnology applications. Ovagen Group Ltd. (OGL) is an innovation-based biotechnology company, led by serial entrepreneurs, providing specialist contract services to Biopharma, Pharmaceutical and Vaccine industries. OGL specialises in avian Germ-Free (GF) technology and avian transgenics to Good Manufacturing Practice standards. The company’s vision is to be the go-to supplier of superior quality GF eggs to the vaccine industry globally by 2021.

INNOVATION: The founders Dr Leonard Moran CEO and Dr Catherine Caulfield COO together with external VC investors and Enterprise Ireland have invested €12.91M in seven years of R&D, utilising the considerable skills, expertise and experience of our team within this field to develop a unique and novel, patent protected process to enable commercially viable production of the World’s first germ-free (GF) eggs, to eliminate bacterial contamination through eggs for vaccine development and production. This will result in improved quality, production costs and viral yields for vaccine manufacturers leading to cost and availability benefits for health service providers for immunisation programmes to protect the health and lives of populations whilst enabling a rapid response to Global pandemic demands. There is exceptionally strong market pull for our innovative disruptive technology, and the increasing use of vaccines to support global demand for quality eggs estimated CAGR of 8.8% and market value of USD 1.89Bn by 2022.

OPPORTUNITY: Over 1bn fertilised specific pathogen free (SPF) chicken eggs are used annually in vaccine manufacture, servicing a vaccine market size estimated to be worth €48bn by 2021 with an AGR of 8.3%.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OVAVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OVAVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More